Jay Stout
Direttore Tecnico/Scientifico/R&S presso IMMUNOVANT, INC.
Patrimonio netto: 4 M $ in data 31/05/2024
Profilo
Jay Stout is currently the Chief Technology Officer at Immunovant, Inc. He previously worked as the Chief Technical Officer at Immunomedics, Inc. and as the Senior Vice President-Technical Operations at Versartis, Inc. Stout received his undergraduate and graduate degrees from the University of Iowa and his doctorate from The University of Nebraska-Lincoln.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
IMMUNOVANT INC
0.10% | 24/04/2024 | 147 739 ( 0.10% ) | 4 M $ | 31/05/2024 |
Posizioni attive di Jay Stout
| Società | Posizione | Inizio |
|---|---|---|
| IMMUNOVANT, INC. | Direttore Tecnico/Scientifico/R&S | 01/04/2023 |
Precedenti posizioni note di Jay Stout
| Società | Posizione | Fine |
|---|---|---|
| IMMUNOMEDICS, INC. | Direttore Tecnico/Scientifico/R&S | - |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Jay Stout
| The University of Nebraska-Lincoln | Doctorate Degree |
| University of Iowa | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| IMMUNOVANT, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
- Borsa valori
- Insiders
- Jay Stout
